Chiron Sues Corus Pharma For Stealing Trade Secrets

Law360, New York (December 8, 2004, 12:00 AM EST) -- Biotech company Chiron has sued Seattle startup Corus Pharma, which is preparing to go public, for allegedly misappropriating trade secrets underpinning the development of an inhalable drug for cystic fibrosis.

The complaint accuses Corus and two executives, including chief executive Bruce Montgomery, of violating employment agreements they worked under at Pathogenesis, which was sold to Chiron for about $700 million in August 2000.

Montgomery, the former vice president of research and development at PathoGenesis, helped Genentech Inc. develop the cystic fibrosis treatment Pulmozyme before joining the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.